PIA
ALNY icon

Piedmont Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Piedmont Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,909
Closed -$861K – 30
2020
Q1 		$861K Buy
7,909
+1,223
+18% +$141K 0.03% 325
2019
Q4 		$770K Buy
6,686
+113
+2% +$11.3K 0.03% 394
2019
Q3 		$529K Buy
6,573
+38
+0.6% +$3.01K 0.02% 496
2019
Q2 		$474K Buy
6,535
+417
+7% +$32K 0.02% 568
2019
Q1 		$572K Buy
6,118
+371
+6% +$31K 0.02% 464
2018
Q4 		$419K Buy
5,747
+22
+0.4% +$1.69K 0.02% 532
2018
Q3 		$501K Buy
5,725
+5,721
+143,025% +$575K 0.02% 515
2018
Q2 		$0 Buy
+4
New +$397 ﹤0.01% 2875

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Piedmont Investment Advisors's ALNY Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 7,909 shares — an estimated $861K sold.

Piedmont Investment Advisors first reported a position in ALNY in Q2 2018 and held it in 8 quarters. The position peaked at $861K in Q1 2020. 375 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

  • Piedmont Investment Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 7,909 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $861K.
  • Piedmont Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • Piedmont Investment Advisors's Alnylam Pharmaceuticals position peaked at $861K in Q1 2020.
  • 375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.